<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AA7CF37A-1A3C-4DC6-8488-4445B285ACA2"><gtr:id>AA7CF37A-1A3C-4DC6-8488-4445B285ACA2</gtr:id><gtr:name>Genentech</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DC2BC2B1-8A47-4F73-906C-81A41CB24BCD"><gtr:id>DC2BC2B1-8A47-4F73-906C-81A41CB24BCD</gtr:id><gtr:name>Biogen Idec</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AA7CF37A-1A3C-4DC6-8488-4445B285ACA2"><gtr:id>AA7CF37A-1A3C-4DC6-8488-4445B285ACA2</gtr:id><gtr:name>Genentech</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DC2BC2B1-8A47-4F73-906C-81A41CB24BCD"><gtr:id>DC2BC2B1-8A47-4F73-906C-81A41CB24BCD</gtr:id><gtr:name>Biogen Idec</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/ADD8049D-3CA3-403E-907C-BCCAA6D666BC"><gtr:id>ADD8049D-3CA3-403E-907C-BCCAA6D666BC</gtr:id><gtr:firstName>Lars</gtr:firstName><gtr:surname>Fugger</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_UU_12010%2F3"><gtr:id>C9C8B490-B9F5-4776-81B0-9D6EB9CBAD84</gtr:id><gtr:title>Multiple sclerosis and the Major Histocompatibility Complex</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_UU_12010/3</gtr:grantReference><gtr:abstractText>My group is studying the genes involved in the pathogenesis of multiple sclerosis so that effective therapies may be developed. Several genes have been shown to contribute to MS susceptibility ? for example the KIR receptors that are expressed on immune cells called NK cells, tumour necrosis factor-receptor 1, the interleukin-7 receptor alpha chain, and the (e) the T-box transcription factor eomesodermin (EOMES) gene region. These genes are very close to each other on the chromosomes, and so it has been difficult to work out their relative importance. We have developed methods that will allow us to study each of these genes in isolation, and determine how each contributes to the pathogenecity of MS. Data from our studies will be used in the development of new and more effective therapies for this debilitating disease.</gtr:abstractText><gtr:technicalSummary>Goals To provide a functional understanding of how MHC class I and class II genes confer risk to multiple sclerosis (MS). Our research has focussed predominantly on exploring the pathogenesis of a HLA-associated disease of the central nervous system ? multiple sclerosis (MS). We have translated MS-associated genotypes to phenotypes and in doing so have shed light on disease mechanisms and provided therapeutic opportunities. We have shown that the DRB1*1501 allele is the primary risk gene in MS and that its disease-mediating effect can be modified by the linked DRB5*0101 (1). We have demonstrated functional interactions between MS associated genes and shown how protective genes can regulate risk genes, leading to less severe disease (1-4). Further, we have determined the functional and structural bases for interactions between MS-risk genes and environmental factors. Our studies in autoimmune encephalomyelitis (EAE) an animal model of MS, have shown that the acid sensitive ion channel ASIC1 is important in pathogenesis. Tissue acidosis in the spinal cord of EAE mice causes the ASIC1 channels to open, and as these are permeable to Na+ and Ca2+ ions (2) the clinical deficit and axonal degeneration caused by excessive accumulation of these two ions is reduced. Thus we have identified this acid sensing ion channel as a potential therapeutic target in MS. Future research plans Future work will focus on the study of several immune genes showing MS associated variations by using humanized and transgenic mouse models: (a) the KIR receptors that are expressed on NK cells, and their interaction with difference HLA-C alleles; (b) tumour necrosis factor-receptor 1; (c) the interleukin-7 receptor alpha chain; and the (e) the T-box transcription factor eomesodermin (EOMES) gene region. We will also carry out multiple MS family whole genome sequencing. References: (1) Gregersen et al 2006 Nature 443:574 (2) Friese et al 2007 Nature Med 12:1483 (3) Friese et al 2008 Nature Med 14: 1227 (4) Harkiolaki et al 2009 Immuity 30: 348 (5) Fugger et al 2009 Nature Rev Immunol 9: 408.</gtr:technicalSummary><gtr:fund><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>2195000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs><gtr:artisticAndCreativeProductOutput><gtr:description>A 2.4 minutes animation of how a gene confers risk to multiple sclerosis</gtr:description><gtr:id>8E3F3812-3D6A-4C1D-891D-B913C26D974B</gtr:id><gtr:impact>Convey the message to professionals and laypersons in an understandable manner</gtr:impact><gtr:outcomeId>54621d04d27a96.16435248</gtr:outcomeId><gtr:title>How a gene confers risk to multiple sclerosis</gtr:title><gtr:type>Film/Video/Animation</gtr:type><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:artisticAndCreativeProductOutput></gtr:artisticAndCreativeProductOutputs><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Genentech</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Structural characterisation of TYK2-homologous JAK2 Ala1057 kinase domain</gtr:description><gtr:id>1374BE0A-2580-42B9-903B-27BF5B5D015B</gtr:id><gtr:impact>Publication of this work in November 2016 in Science Translational Medicine (http://stm.sciencemag.org/content/8/363/363ra149.full)</gtr:impact><gtr:outcomeId>58a6f66b44eef3.27203506-1</gtr:outcomeId><gtr:partnerContribution>Genentech performed the crystallography and relevant biological analysis for the project.</gtr:partnerContribution><gtr:piContribution>We formed a collaboration with a team of scientists at Genetech, in order to resolve the crystal structure of TYK2-homologous JAK2 Ala1057 kinase domain.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Genentech</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Functional genetics in multiple sclerosis</gtr:description><gtr:id>D61BA71E-298E-4F40-AC00-2EB3B28630E4</gtr:id><gtr:impact>None os far. Work is in progress.</gtr:impact><gtr:outcomeId>546217530ada53.63663370-1</gtr:outcomeId><gtr:partnerContribution>Structural study of multiple sclerosis gene</gtr:partnerContribution><gtr:piContribution>Functional study of multiple sclerosis gene</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Biogen Idec</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Infectious risk factors in multiple sclerosis</gtr:description><gtr:id>9630A9A2-416C-4825-AC6C-D2A1448C8AC9</gtr:id><gtr:impact>None so far. Work in progress.</gtr:impact><gtr:outcomeId>546217df001ed2.27262981-1</gtr:outcomeId><gtr:partnerContribution>DNA sequences from patients afflicted by PML</gtr:partnerContribution><gtr:piContribution>DNA sequences from patients afflicted by PML</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>MS Oxford Patient Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>9E57B44B-B693-4D41-85D8-3209074F6414</gtr:id><gtr:impact>MS patients and their relatives are invited to come and listen to talks given by researcher in Oxford in order to give them the opportunity about the research that is being invested into MS, and the treatments that are currently available or may be in the future.</gtr:impact><gtr:outcomeId>58a6f8808f6224.07938853</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Meeting with MS patients and their families</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>6093E4F3-0A40-48ED-A0FC-E85C5172DA03</gtr:id><gtr:impact>better understanding of MS and how it is being treated now and in the future

Positive feedback</gtr:impact><gtr:outcomeId>5462190704b804.16981161</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011,2012,2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>TV programme</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>0E5755C9-2D6C-4CC6-AAE1-59EE9D37F744</gtr:id><gtr:impact>TV programme

Public awareness of our research</gtr:impact><gtr:outcomeId>35F027EF878</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MS Life patient day</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>863E0187-C7F0-4E9D-A9C2-1C3CEC809B42</gtr:id><gtr:impact>Talk given to MS patients at an organised MS Life event in London to discuss the outcomes of research into amiloride that originated from our research. The talk was entitled, 'when things go sour'.</gtr:impact><gtr:outcomeId>58a6f80a733f36.87817153</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member of Science Europe</gtr:description><gtr:geographicReach>Asia</gtr:geographicReach><gtr:id>04F4664A-4073-42A4-8F88-584C56DD5D08</gtr:id><gtr:impact>Vivi section and access to big data</gtr:impact><gtr:outcomeId>54621a2737ffa3.45122168</gtr:outcomeId><gtr:type>Citation in other policy documents</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>965893A8-644A-4347-BBF2-8A78B5006B34</gtr:id><gtr:title>TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/91d8bb4f92e8f39b6ef17c958444f58c"><gtr:id>91d8bb4f92e8f39b6ef17c958444f58c</gtr:id><gtr:otherNames>Gregory AP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>pm_13706_26_22801493</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E06F497A-6711-4FBC-BFA1-5689039DBB77</gtr:id><gtr:title>Structural and regulatory diversity shape HLA-C protein expression levels.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fb9c73b502f81abc35638f4e65342b3e"><gtr:id>fb9c73b502f81abc35638f4e65342b3e</gtr:id><gtr:otherNames>Kaur G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>5a9e86a0f3a6e9.04932309</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3C8AE420-979C-480C-88C1-9B0C68668B5E</gtr:id><gtr:title>Bayesian analysis of genetic association across tree-structured routine healthcare data in the UK Biobank.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/db483ff6fd1cd26ef9ee23930f93e016"><gtr:id>db483ff6fd1cd26ef9ee23930f93e016</gtr:id><gtr:otherNames>Cortes A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>5a9e86a0c751f0.40858056</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D8D78EC-F180-4E9A-A683-422454C21E53</gtr:id><gtr:title>TCR transgenic mice that shed light on immune and environmental regulators in multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7582aaffb949998b4e79f74f91a71a19"><gtr:id>7582aaffb949998b4e79f74f91a71a19</gtr:id><gtr:otherNames>Attfield KE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>pm_13706_26_23526826</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E7B2D592-4F42-45B0-9FA1-F4A6027040E0</gtr:id><gtr:title>Immunomodulation in multiple sclerosis: promises and pitfalls.</gtr:title><gtr:parentPublicationTitle>Current opinion in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9e1d45f93dc16ac93d528a5efa49aa6c"><gtr:id>9e1d45f93dc16ac93d528a5efa49aa6c</gtr:id><gtr:otherNames>Dendrou CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0952-7915</gtr:issn><gtr:outcomeId>5a2fd8afb59d57.19336188</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CB2C2FF1-13E7-41AB-B2E7-2A9CBEAC416E</gtr:id><gtr:title>Natural killer cells and their receptors in multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fb9c73b502f81abc35638f4e65342b3e"><gtr:id>fb9c73b502f81abc35638f4e65342b3e</gtr:id><gtr:otherNames>Kaur G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>pm_13706_26_22734127</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>48FE8AA7-963B-4674-8D77-30249E14C4E8</gtr:id><gtr:title>Genomewide association studies and common disease--realizing clinical utility.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dfd30e9e606c194dffc5c461b84c98d6"><gtr:id>dfd30e9e606c194dffc5c461b84c98d6</gtr:id><gtr:otherNames>Fugger L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>pm_13706_26_23252523</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>64DE3FFE-E9ED-475C-948B-364F1915EB21</gtr:id><gtr:title>Factors influencing success of clinical genome sequencing across a broad spectrum of disorders.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0595a7d8bf7c30b67c83c71fcc8d9e98"><gtr:id>0595a7d8bf7c30b67c83c71fcc8d9e98</gtr:id><gtr:otherNames>Taylor JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>56c2ffcf86e903.82911164</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>26B1323C-BBFD-4129-B8A6-E0482D7EEC83</gtr:id><gtr:title>A clinical conundrum: the detrimental effect of TNF antagonists in multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>Pharmacogenomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9e1d45f93dc16ac93d528a5efa49aa6c"><gtr:id>9e1d45f93dc16ac93d528a5efa49aa6c</gtr:id><gtr:otherNames>Dendrou CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1462-2416</gtr:issn><gtr:outcomeId>pm_13706_26_24024893</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F9985551-16FA-47EA-84F3-A5553CBC3A98</gtr:id><gtr:title>Bridging the gap from genetic association to functional understanding: the next generation of mouse models of multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>Immunological reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7582aaffb949998b4e79f74f91a71a19"><gtr:id>7582aaffb949998b4e79f74f91a71a19</gtr:id><gtr:otherNames>Attfield KE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0105-2896</gtr:issn><gtr:outcomeId>pm_13706_26_22725951</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2EF0B38B-796F-4CC5-A5D8-E08141EE98D9</gtr:id><gtr:title>Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity.</gtr:title><gtr:parentPublicationTitle>Science translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9e1d45f93dc16ac93d528a5efa49aa6c"><gtr:id>9e1d45f93dc16ac93d528a5efa49aa6c</gtr:id><gtr:otherNames>Dendrou CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1946-6234</gtr:issn><gtr:outcomeId>58a6f2faa9fb83.77371575</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C1EA8C51-DB8E-4745-AF83-23B0C0E5ABD4</gtr:id><gtr:title>Neuroinflammation - using big data to inform clinical practice.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9e1d45f93dc16ac93d528a5efa49aa6c"><gtr:id>9e1d45f93dc16ac93d528a5efa49aa6c</gtr:id><gtr:otherNames>Dendrou CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1759-4758</gtr:issn><gtr:outcomeId>58a6f2faf08035.19108122</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_UU_12010/3</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>